Optibrium Goes from Strength to Strength as Global Customer Base Continues to Grow
News Sep 21, 2012
Optibrium has revealed a period of growth across all areas of its business. Optibrium is celebrating significant expansion in its team of experts, requiring relocation to new, larger premises. This success is built on the rapidly expanding, global customer base for Optibrium’s primary product, StarDrop. This pioneering drug discovery software platform offers a range of intuitive tools and technologies that guide the selection and design of high quality compounds in drug discovery.
Optibrium, which was founded in 2009, now boasts a customer base of over 50 pharma, biotech and academic groups spread across the globe, including seven of the top ten pharmaceutical companies. All have been attracted by StarDrop; a highly visual and easy-to-use software package, which provides a unique environment for multi-parameter optimisation of candidate drugs. It includes an interactive designer that helps to explore optimisation strategies, guided by StarDrop’s unique Glowing Molecule visualisation. The suite is complemented by a range of plug-in modules that further expand its capabilities to quickly identify better molecules, thereby reducing costs and timelines and strengthening pipelines. Reflecting the growth of the business, Optibrium has expanded its software development and support teams to maintain the high level of support provided to its users and this has required the company to move to office space which is 50% larger than its original premises.
The most recent appointment has seen Nick Foster join as Director of Business Development. Nick’s role will see him lead the development of new business opportunities for Optibrium’s products. Nick has 20 years of experience within the life science industry and academia and joins Optibrium from BioFocus. Nick’s successful track record in business development is complemented by his early scientific career, spent as an ADME/PK scientist working on drug discovery projects.
Nick comments, “I am delighted to be joining the Optibrium team. The company has a fantastic reputation in the industry for its innovative products and offers a dynamic place to work. I look forward to developing our customer base and being part of Optibrium’s continuing expansion and success.”
CEO Matt Segall comments, “Over the past three years our team has developed our product portfolio and introduced innovative approaches to drug discovery as we expanded our customer base. We have now reached a really exciting phase of rapid growth as the result of this hard work and this provides further inspiration to the whole team who are dedicated to finding ways to help scientists to optimise drug discovery.”
U.S. Study of Dapivirine Ring in Lactating Women Finds Little Drug Gets Into Breast MilkNews
The antiretroviral drug dapivirine that is released from an experimental vaginal ring to protect against HIV is absorbed in very low concentrations into breastmilk.READ MORE
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
BioAscent Announces New CEO and Plans to Expand Discovery Services OfferingNews
BioAscent Discovery Limited appoints new CEO, Paul Smith in preparation for the expansion of companies discovery services.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018